Timotius Ivan Hariyanto

Dr. Timotius Ivan Hariyanto

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in The American Journal of Emergency Medicine
Verified
Journal Article
Closed access
THTimotius Ivan Hariyanto
Timotius Ivan Hariyanto
KJKarunia Valeriani Japar
Karunia Valeriani Japar
FKFelix Kwenandar
Felix Kwenandar
VDVika Damay
Vika Damay
JSJeremia Immanuel Siregar
Jeremia Immanuel Siregar
AKAndree Kurniawan
Andree Kurniawan


1 September 2020 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Verified
Journal Article
Closed access
THTimotius Ivan Hariyanto
Timotius Ivan Hariyanto
AKAndree Kurniawan
Andree Kurniawan

1 August 2020 in IJC Heart & Vasculature
Verified
Journal Article
Open access
FKFelix Kwenandar
Felix Kwenandar
KJKarunia Valeriani Japar
Karunia Valeriani Japar
VDVika Damay
Vika Damay
THTimotius Ivan Hariyanto
Timotius Ivan Hariyanto
MTMichael Tanaka
Michael Tanaka
AKAndree Kurniawan
Andree Kurniawan
At the end of 2019, a viral pneumonia disease called coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV2), emerged in Wuhan, China. This novel disease rapidly spread at an alarming rate that as a result, it has now been declared pandemic by the World Health Organization. Although this infective disease is mostly characterized by respiratory tract symptoms, increasing numbers of evidence had shown considerable amounts of patients with cardiovascular involvements and these were associated with higher mortality among COVID-19 patients. Cardiac involvement as a possible late phenomenon of the viral respiratory infection is an issue that should be anticipated in patients with COVID-19. Cardiovascular manifestation in COVID-19 patients include myocardial injury (MI), arrhythmias, cardiac arrests, heart failure and coagulation abnormality, ranging from 7.2% up to 33%. The mechanism of cardiac involvement in COVID-19 patients involves direct injury to myocardial cells mediated by angiotensin-converting enzyme 2 (ACE2) receptors as suggested by some studies, while the other studies suggest that systemic inflammation causing indirect myocyte injury may also play a role. Combination of proper triage, close monitoring, and avoidance of some drugs that have cardiovascular toxicity are important in the management of cardiovascular system involvement in COVID-19 patients. The involvement of the cardiovascular system in COVID-19 patients is prevalent, variable, and debilitating. Therefore, it requires our attention and comprehensive management.


1 December 2020 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
THTimotius Ivan Hariyanto
Timotius Ivan Hariyanto
AKAndree Kurniawan
Andree Kurniawan